FreeTheAI

Sanofi Options First Immunology Candidate from Recursion AI Collaboration

BullishMedium impact
RXRX$3.89 4.01%SAN€72.17 0.49%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) disclosed that Sanofi SA (EURONEXT:SAN) has exercised its option on an initial drug candidate generated through their ongoing research partnership. The asset is a potential first-in-class oral small molecule intended to treat inflammatory diseases by targeting two biological markers at once. Sanofi's selection triggers a $10 million milestone payment to Recursion, bringing its total revenue collected from the deal to $144 million.

The candidate represents an operational success for Recursion's AI-assisted discovery platform, which worked to resolve intricate design constraints. Recursion will record the $10 million in revenue during the third quarter of 2026. Because Recursion has fulfilled its technical responsibilities for this specific compound, any subsequent milestone payments—which could exceed $300 million—plus double-digit royalties on future sales will directly contribute to profit.

Sanofi assumes full responsibility for all upcoming development, clinical trials, and potential marketing efforts. A Phase 1 clinical trial is slated to start in 2027. Over the next 12 months, investors can watch for potential development progress across other joint programs in the partnership.

Key points

  • Sanofi optioned an oral small molecule candidate targeting inflammatory diseases developed using Recursion's AI platform.
  • Recursion receives a $10 million milestone payment, bringing total cash received from the collaboration to $144 million.
  • Sanofi will fully fund and run future development, with Phase 1 clinical trials targeted for 2027.
  • Recursion remains eligible for more than $300 million in potential future milestones plus double-digit sales royalties.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did Sanofi announce regarding Recursion Pharmaceuticals?

Sanofi optioned its first drug candidate from its collaboration with Recursion Pharmaceuticals. The candidate is a potential first-in-class oral small molecule for inflammatory diseases.

How much money does Recursion receive from Sanofi's option exercise?

Recursion will receive a $10 million milestone payment, recognized in the third quarter of 2026. This brings total payments under the collaboration to $144 million, with up to $300 million in potential future milestones.

When will clinical trials begin for the new drug candidate?

Sanofi plans to begin Phase 1 clinical trials for the newly optioned immunology drug candidate in 2027.